stockrow
Friday 6 November 2026
Export FBIO’s income statement to Excel — free account
Fortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −116.0%
- Free cash flow
- −115.4%
- Total debt
- −35.7%
Quarter to June 2026, against a year earlier
1.85
0.01
+0.54%
Follow FBIO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 7 | 5 | 3 |
+8 more TTM periods Free account |
| 84.91% | 101.51% | (6.22%) | (20.35%) | ||
| 43.38% | 44.56% | (1.14%) | (3.46%) | ||
ROIC |
(41.34%) | 0.00% | (124.61%) | (209.25%) | |
Return on Tangible Assets |
55.60% | 61.28% | (2.46%) | (7.96%) | |
Average Days of Receivables |
195.93 | 140.72 | 172.75 | 106.18 | |
Free Cash Flow per Share |
3.96 | 5.00 | (2.32) | (2.39) | |
Free Cash Flow |
125.84 | 157.64 | (64.61) | (65.04) | |
Capital Expenditures |
(0.08) | — | 1.17 | 1.10 | |
| Other line items | |||||
Cash ROIC |
28.78% | 31.84% | (33.31%) | (32.65%) | |
Accounts Receivable Turnover |
2.59 | 3.02 | 3.14 | 4.30 | |
Accounts Payable Turnover |
0.48 | 0.28 | 0.37 | 0.37 | |
Inventory Turnover |
2.24 | 2.05 | 1.74 | 1.71 | |
Average Days of Payables |
764.29 | 1,518.43 | 822.05 | 817.71 | |
Days of Inventory on Hand |
126.38 | 151.74 | 167.88 | 213.93 | |
Tax Rate |
(0.03) | (0.03) | (0.02) | 0.01 | |
Research and Development Expense of Revenue |
1.73% | 12.85% | 18.81% | 35.63% | |
Selling, General and Administrative Expense of Revenue |
100.31% | 130.94% | 152.38% | 174.64% | |
Share Based Compensation of Revenue |
15.03% | 37.53% | 45.43% | 68.17% | |
Interest Coverage |
(3.03) | (5.22) | (6.95) | (8.40) | |
Operating CF/Net income |
1.22 | 1.32 | 34.95 | 12.39 | |
Depreciation/Fixed assets |
3.67 | 3.79 | 3.18 | 3.04 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.15 | 0.14 | |
Revenue per Share |
2.15 | 2.10 | 2.27 | 2.29 | |
Operating CF per Share |
3.96 | 5.00 | (2.36) | (2.43) | |
Capex per Share |
0.00 | 0.00 | 0.04 | 0.04 | |
Capex to Sales |
0.00 | 0.00 | (0.02) | (0.02) |
Columns are period end dates